The role of the GABA B receptor and calcium channels in a Drosophila model of Parkinson's Disease

Neuroscience Letters

Volumn 516, Issue 2, 2012, Pages 167-170

  Hillman, Ralph ^a   Sinani, Jonida ^a   Pendleton, Robert ^a  

^a Temple University   (United States)

Author keywords

Alpha synuclein; Calcium channels; GABA B receptor; Parkinson's Disease

Indexed keywords

2 HYDROXYSACLOFEN; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ALPHA SYNUCLEIN; BACLOFEN; CALCIUM CHANNEL; FENDILINE; LEVODOPA; MUSCIMOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CLIMBING; DROSOPHILA MELANOGASTER; LOCOMOTION; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; GABA-B RECEPTOR AGONISTS; GABA-B RECEPTOR ANTAGONISTS; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; RECEPTORS, GABA-B;

EID: 84860453973     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.03.034     Document Type: Article

References (28)

1. Bayer R., Mannhold R. Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 1987, 5:103-136.
2. Becker C., Jick S.S., Meier C.R. Use of antihypertensives and the risk of Parkinson's Disease. Neurology 2008, 70:1438-1444.
3. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M., Sudhof T.C α-Synuclein promotes SNARE-complex in vivo and in vitro. Science 2010, 329:1663-1667.
4. B receptors modulate NMDA receptor calcium signals in dendritic spines. Neuron 2010, 66:101-113.
5. Chan C.S., Gertler T.S., Surmeier D.J. Calcium homeostasis, selective vulnerability and Parkinson's Disease. Trends in Neurosciences 2009, 32:249-256.
6. Cookson M.R., Bandman O. Parkinson's disease: insights from pathways. Human Molecular Genetics 2010, 19(R1):R21-R27.
7. Dang K., Bowery N.G., Urban L. Interaction of γ-aminobutyric acid receptor type B receptors and calcium channels in nocisected transmission studied in the mouse hemisected spinal cord in vitro: withdrawal symptoms related to baclofen treatment. Neuroscience Letters 2004, 361:72-75.
8. B receptors in a rodent model of Parkinson's Disease. Neuropharmacology 1999, 38:1683-1989.
9. B receptors. Membrane Biophysics and Biochemistry 2000, 11:3431-3434.
10. B receptors: structure and function. Progress in Brain Research 2007, 160:43-57.
11. Feany M.B., Bender W.W. A Drosophila model of Parkinson's Disease. Nature 2000, 404:394-398.
12. Hirsch J., Erlenmeyer-Kimling L. Studies in experimental behavior genetics: IV. Chromosome analysis for geotaxis. Journal of Comparative and Physiological Psychology 1962, 55:732-739.
13. B receptor agonists reverse akinesia following intranigral or intracerebroventricular injection in the reserpine-treated rat. British Journal of Pharmacology 2003, 139:1480-1486.
14. B receptors in rat neocortex. European Journal of Pharmacology 2002, 451:69-77.
15. Lees A.J., Shaw K.M., Stern G.M. Baclofen in Parkinson's Disease. Journal of Neurology, Neurosurgery and Psychiatry 1978, 41:707-708.
16. Lowe R., Pountney D.L., Jensen P.H., Gal W.P., Voelcker N. Calcium(II) selectively induces a-synuclein annular oligomers via interaction with the C-terminal domain. Protein Science 2004, 13:3245-3252.
17. Mosharov E.V., Larsen K.L., Kanter E., Phillips K.A., Wilson K., Schmitz Y., Krantz D.E., Kobayashi K., Edwards R.H., Sulzer D. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
18. 2+ binding to α-synuclein regulates ligand binding and oligomerization. The Journal of Biological Chemistry 2001, 276:2260-22684.
19. B receptor modulators. CNS Drug Reviews 2005, 11:317-334.
20. Parkinson's Study Group Levodopa and the progression of Parkinson's Disease. The New England Journal of Medicine 2004, 351:2498-2508.
21. Pendleton R.G., Parvez F., Sayed M., Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's Disease in Drosophila melanogaster. The Journal of Pharmacology and Experimental Therapeutics 2002, 300:91-96. [Erratum, J. Pharmacol. Exp. Ther. 300 1131].
22. Surmeier D.J., Guzman J.M., Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's Disease. Cell Calcium 2010, 47:175-182.
23. Tamamizu-Kato S., Kosaraju M.G., Kato H., Raussens V., Ruysschaert J., Narayanaswami V. Calcium-triggered membrane interaction of the α-synuclein acidic tail. Biochemistry 2006, 45:10947-10956.
24. Tepper J.M., Lee C.R. GABAergic control of substantia nigra dopaminergic neurons. Progress in Brain Research 2007, 160:189-208.
25. Tripathi O., Schreibmayer W., Tritthart H.A. Fendiline inhibits L-type calcium channels in guinea-pig myocytes: a whole-cell patch-clamp study. British Journal of Pharmacology 1993, 108:865-869.
26. Urwyler S., Mosbacher J., Lingenhoel K., Heid J., Hofstetter K., Froestl W., Bettler B., Kaupmann K. Positive allosteric modulation of native and recombinant (-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analogue CGP13501. Molecular Pharmaceutics 2001, 60:963-971.
27. 1-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of γ-aminobutyric acidB receptor function. The Journal of Pharmacology and Experimental Therapeutics 2003, 307:322-330.
28. Walton P.D. The genetics of geotaxis in Drosophila melanogaster. Canadian Journal of Genetics and Cytology 1968, 10:673-687.